Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the space for growth in the future, especially via the reimbursement of parallel imported products. Furthermore, he touches on the relationship with the key stakeholders, and the importance of the verified medicines plan for the nation to be implemented in 2019.
What was the reasoning to start the company in 2004?
"Our next step is reimbursement, which will open up the same opportunities as many other major European market."
